JPRN-jRCT2080222242未知3 期
Phase 3 Study of ASP2151 in Herpes Zoster Patients - A Double-blind,Valaciclovir-controlled Study
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •(1) Patients who have a rash associated with herpes zoster, and who can start receiving the study drug within 72 hours after onset of the rash
排除标准
- •(1) Patients who are not expected to have an adequate response to oral antiviral medication
- •(2) An extreme decline in immune function
- •(3) Presence of serious complications
- •(4) Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent:
- •1) AST or ALT >= 2.5 x upper limit of normal
- •2) Platelet count < lower limit of normal
- •3) Serum creatinine >= 1.5 mg/dL
- •4) Creatinine clearance < 50 mL/min
- •(5) Current or previous history of malignant tumor within 5 years before informed consent
- •(6) Diagnosis of autoimmune disease
- •(7) Evidence of bone marrow suppression
研究者
相似试验
已完成
3 期
Phase III Study of ASP2151 in Herpes Zoster PatientsHerpes ZosterNCT01959841Maruho Co., Ltd.751
已完成
3 期
Phase III Study of ASP2151 in Herpes Simplex PatientsHerpes SimplexNCT01959295Maruho Co., Ltd.468
已完成
3 期
Phase 3 Study of ASP2151 in Herpes Simplex Patients -A Double-blind,Placebo-controlled Studyherpes simplex (labial/facial herpes or recurrent genital herpes)JPRN-jRCT2080222243Maruho Co.,Ltd.468
已完成
3 期
Open-label Study of ASP2151 in Herpes Simplex PatientsRecurrent herpes simplex (labial/facial herpes and recurrent genital herpes) and Kaposi varicelliform eruptionJPRN-jRCT2080222573Maruho Co.,Ltd.275
已完成
2 期
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital HerpesHerpes GenitalisNCT00486200Astellas Pharma Inc695